Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Durvalumab |
| Synonyms | |
| Therapy Description |
Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA-approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with platinum-based chemotherapy as neoadjuvant therapy followed by surgery and adjuvant Imfinzi (durvalumab) in patients with resectable non-small cell lung cancer, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with carboplatin plus paclitaxel followed by single-agent Imfinzi (durvalumab) in adult patients with mismatch repair deficient endometrial cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA-approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with platinum-based chemotherapy as neoadjuvant therapy followed by surgery and adjuvant Imfinzi (durvalumab) in patients with resectable non-small cell lung cancer, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with carboplatin plus paclitaxel followed by single-agent Imfinzi (durvalumab) in adult patients with mismatch repair deficient endometrial cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | lung non-small cell carcinoma | no benefit | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Durvalumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). | 27225694 |
| MSH6 negative | endometrial cancer | sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). | 34103352 |
| MSH6 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | 36696825 detail... |
| MSH6 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | detail... 35690222 |
| MLH1 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | 35690222 detail... |
| MLH1 negative | endometrial cancer | sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). | 34103352 |
| MLH1 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | 36696825 detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04078152 | FDA approved | Durvalumab | Durvalumab Long-Term Safety and Efficacy Study (WAVE) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 11 |
| NCT05757843 | Phase II | Durvalumab | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | Withdrawn | 0 | |
| NCT02221960 | Phase I | Durvalumab Efizonerimod | A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 0 |
| NCT03847649 | Phase II | Durvalumab Durvalumab + Prednisone | Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity | Recruiting | CAN | 0 |
| NCT03206073 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | Completed | USA | 0 |
| NCT03459846 | Phase II | Durvalumab + Olaparib Durvalumab | A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) | Active, not recruiting | USA | ESP | CAN | 4 |
| NCT03196401 | Phase I | Durvalumab | A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma | Withdrawn | USA | 0 |
| NCT05215106 | Phase II | Durvalumab | Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA) | Recruiting | FRA | 0 |
| NCT02179671 | Phase II | Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | Completed | USA | 0 |
| NCT03833154 | Phase III | Durvalumab | Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 5 |
| NCT02262741 | Phase I | Tremelimumab Durvalumab | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer | Completed | USA | CAN | 0 |
| NCT02319044 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 4 |
| NCT06211036 | Phase III | Durvalumab + Tarlatamab Durvalumab | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | Recruiting | USA | TUR | CHE | BRA | AUS | ARG | 5 |
| NCT02205333 | Phase Ib/II | Rituximab MEDI6469 Tremelimumab Durvalumab | A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | Terminated | USA | 0 |
| NCT04786093 | Phase II | Durvalumab | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | Recruiting | USA | 0 |
| NCT04351256 | Phase II | Durvalumab | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo) | Recruiting | DEU | 0 |
| NCT05068232 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | Recruiting | USA | 0 |
| NCT04238637 | Phase II | Durvalumab Durvalumab + Tremelimumab | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | Recruiting | DEU | 0 |
| NCT04866017 | Phase III | Durvalumab BGBA1217 + Tislelizumab Tislelizumab | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Terminated | USA | ESP | AUS | 2 |
| NCT02546661 | Phase I | Danvatirsen + Durvalumab Durvalumab + Selumetinib Fexagratinib Durvalumab + Olaparib Durvalumab Durvalumab + Fexagratinib Durvalumab + Vistusertib Adavosertib + Durvalumab | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | 0 |
| NCT01993810 | Phase III | Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03317158 | Phase Ib/II | Durvalumab BCG solution + Durvalumab | ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder | Recruiting | USA | 0 |
| NCT03298451 | Phase III | Sorafenib Durvalumab + Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BRA | 10 |
| NCT02827838 | Phase I | Durvalumab | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Completed | USA | 0 |
| NCT02669914 | Phase II | Durvalumab | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Terminated | USA | 0 |
| NCT05718297 | Phase II | Brigatinib Durvalumab | Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE) | Withdrawn | POL | ITA | GBR | FRA | ESP | 0 |
| NCT03818776 | Phase I | Durvalumab | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | Terminated | USA | 0 |
| NCT05617963 | Phase II | Durvalumab | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG) | Recruiting | FRA | 0 |
| NCT04513925 | Phase III | Atezolizumab + Tiragolumab Durvalumab | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
| NCT03084471 | Phase III | Durvalumab + Tremelimumab Durvalumab | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) | Completed | USA | NLD | ITA | GBR | FRA | DEU | CAN | 1 |
| NCT03102047 | Phase II | Durvalumab | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | Completed | USA | 0 |
| NCT03150836 | Phase II | Durvalumab Durvalumab + Tremelimumab | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | Withdrawn | USA | 0 |
| NCT02087423 | Phase II | Durvalumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) | Active, not recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | 6 |
| NCT02901548 | Phase II | Durvalumab | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | Terminated | USA | 0 |
| NCT02535078 | Phase Ib/II | Durvalumab Tebentafusp Tremelimumab | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma | Withdrawn | USA | 0 |
| NCT05568212 | Phase II | Durvalumab Durvalumab + Olaparib | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | Recruiting | ITA | 0 |
| NCT04870112 | Phase Ib/II | Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) | Terminated | USA | NZL | ESP | 1 |
| NCT03015129 | Phase II | Durvalumab Durvalumab + Tremelimumab | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | Completed | USA | 0 |
| NCT03589547 | Phase II | Durvalumab | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | Active, not recruiting | USA | 0 |
| NCT04597671 | Phase III | Durvalumab | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28) | Recruiting | NLD | 0 |
| NCT04441138 | Phase II | Durvalumab | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205) | Suspended | USA | 0 |
| NCT02369874 | Phase III | Durvalumab + Tremelimumab Durvalumab | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | Completed | USA | ROU | POL | ITA | ISR | HUN | HRV | FRA | ESP | DEU | CZE | BRA | BGR | BEL | AUS | ARG | 8 |
| NCT02966587 | Phase II | Durvalumab | Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Withdrawn | USA | 0 |
| NCT04602533 | Phase II | Cisplatin + Etoposide Durvalumab | Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | Recruiting | DEU | 0 |
| NCT03245541 | Phase Ib/II | Durvalumab | Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) | Active, not recruiting | USA | 0 |
| NCT04585490 | Phase III | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Paclitaxel | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | Recruiting | USA | 0 |
| NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Active, not recruiting | ITA | GBR | FRA | ESP | BEL | 0 |
| NCT03003962 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | Active, not recruiting | USA | TUR | POL | NLD | HUN | AUS | 6 |
| NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT02592551 | Phase II | Durvalumab + Tremelimumab Durvalumab | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | Completed | USA | 0 |
| NCT02311361 | Phase I | Durvalumab Tremelimumab | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Completed | USA | 0 |
| NCT02639065 | Phase II | Durvalumab | A Study of Durvalumab (MEDI4736) in Esophageal Cancer | Completed | USA | 0 |
| NCT05443971 | Phase II | Durvalumab | Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen | Recruiting | USA | 0 |
| NCT06333678 | Phase II | Durvalumab Sotorasib | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
| NCT03007407 | Phase II | Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | Completed | USA | 0 |
| NCT06045975 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP) | Recruiting | FRA | 0 |
| NCT04748419 | Phase Ib/II | Durvalumab | Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab | Recruiting | USA | 0 |
| NCT03026062 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Combo Versus Sequential | Active, not recruiting | USA | 0 |
| NCT02793466 | Phase I | Durvalumab | Durvalumab in Pediatric and Adolescent Patients | Completed | USA | 0 |
| NCT03889275 | Phase I | Durvalumab Durvalumab + MEDI5395 MEDI5395 | A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors | Completed | USA | GBR | 0 |
| NCT03768570 | Phase II | Durvalumab | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | Active, not recruiting | GBR | ESP | CAN | 0 |
| NCT03490760 | Phase II | Durvalumab | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Terminated | USA | 0 |
| NCT04108026 | Phase II | Durvalumab | Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) | Active, not recruiting | FRA | 0 |
| NCT05303532 | Phase III | Durvalumab | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D) | Enrolling by invitation | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 13 |
| NCT05440864 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA)) | Recruiting | ITA | ESP | CAN | 0 |
| NCT03778957 | Phase III | Durvalumab Bevacizumab + Durvalumab | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BRA | AUS | 11 |
| NCT02503774 | Phase I | Durvalumab Oleclumab | MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 1 |
| NCT03840902 | Phase II | Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | NLD | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
| NCT04364048 | Phase II | Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT02879617 | Phase II | Durvalumab | A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Completed | USA | 0 |
| NCT03773666 | Phase I | Durvalumab + Oleclumab Durvalumab | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | Completed | USA | 0 |
| NCT02301130 | Phase I | Mogamulizumab Durvalumab Tremelimumab | Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | Completed | USA | 0 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT04470674 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients | Withdrawn | USA | 0 |
| NCT03530397 | Phase I | Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | ITA | FRA | ESP | AUS | 3 |
| NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Active, not recruiting | USA | TUR | ROU | POL | NOR | LVA | LTU | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | ARG | 9 |
| NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Active, not recruiting | USA | 0 |
| NCT03635164 | Phase I | Durvalumab | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT02904954 | Phase II | Durvalumab | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer | Completed | USA | 0 |
| NCT03237377 | Phase II | Durvalumab + Tremelimumab Durvalumab | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT05713838 | Phase II | Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Durvalumab | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | Recruiting | DEU | 0 |
| NCT04944173 | Phase II | Durvalumab | A Study of Durvalumab and Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer (SCION) | Withdrawn | CAN | 0 |
| NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | POL | ESP | BEL | AUT | 4 |
| NCT02453282 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 6 |
| NCT03830866 | Phase III | Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) | Completed | USA | POL | HUN | BRA | 11 |
| NCT04716946 | Phase II | Durvalumab | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | Recruiting | USA | 0 |
| NCT03999710 | Phase II | Durvalumab | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03199040 | Phase I | Durvalumab | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | Terminated | USA | 0 |
| NCT05128630 | Phase II | Durvalumab | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS) | Recruiting | ITA | 0 |
| NCT03011814 | Phase Ib/II | Durvalumab Durvalumab + Lenalidomide | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
| NCT03258554 | Phase II | Cetuximab Durvalumab | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin | Active, not recruiting | USA | CAN | 0 |
| NCT03875573 | Phase II | Durvalumab Durvalumab + Oleclumab | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) | Active, not recruiting | FRA | BEL | 0 |
| NCT05221840 | Phase III | Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 11 |
| NCT02616640 | Phase I | Pomalidomide Dexamethasone Durvalumab | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
| NCT03610061 | Phase I | Durvalumab | A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD) | Completed | AUS | 0 |
| NCT03235869 | Phase I | Durvalumab | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | Withdrawn | USA | 0 |
| NCT02125461 | Phase III | Durvalumab | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) | Completed | USA | TUR | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 10 |
| NCT03847428 | Phase III | Durvalumab Bevacizumab + Durvalumab | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) | Active, not recruiting | USA | TUR | POL | ITA | FRA | DEU | CAN | BRA | AUT | AUS | 14 |
| NCT03038477 | Phase II | Durvalumab | A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection | Withdrawn | USA | 0 |
| NCT03618654 | Phase I | Durvalumab + Metformin Durvalumab | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT06464068 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide Durvalumab | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC) | Recruiting | ITA | 0 |
| NCT06083454 | Phase I | Durvalumab Durvalumab + Vitamin C | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
| NCT06290505 | Phase II | Durvalumab | A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study (PALEO) | Recruiting | NZL | AUS | 0 |
| NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
| NCT02273375 | Phase III | Durvalumab | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | Active, not recruiting | USA | ROU | POL | NZL | NLD | ITA | HUN | FRA | ESP | CAN | BRA | BGR | AUS | 6 |
| NCT03907475 | Phase II | Durvalumab Durvalumab + Nab-paclitaxel Capecitabine + Durvalumab Durvalumab + Pegylated liposomal doxorubicin Durvalumab + Gemcitabine Durvalumab + Paclitaxel Carboplatin + Durvalumab | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | Recruiting | USA | 0 |
| NCT03148327 | Phase Ib/II | Durvalumab | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | Active, not recruiting | USA | AUS | 0 |
| NCT04159974 | Phase II | Durvalumab Durvalumab + Tremelimumab | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE) | Active, not recruiting | DEU | 0 |
| NCT04249362 | Phase II | Durvalumab | Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART) | Active, not recruiting | USA | POL | ITA | FRA | ESP | 1 |
| NCT04334759 | Phase III | Durvalumab Cisplatin + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R) | Active, not recruiting | USA | NZL | AUS | 0 |
| NCT02549651 | Phase I | Durvalumab + Tremelimumab Durvalumab Danvatirsen + Durvalumab | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) | Completed | USA | IRL | GBR | FRA | 0 |
| NCT02866747 | Phase Ib/II | Durvalumab | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI) | Active, not recruiting | FRA | 0 |
| NCT02519348 | Phase II | Tremelimumab Durvalumab | A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | ESP | 6 |
| NCT05043090 | Phase III | Durvalumab + Savolitinib Durvalumab Sunitinib | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA) | Recruiting | USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG | 10 |
| NCT05696782 | Phase II | Durvalumab | Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04001413 | Phase II | Durvalumab Durvalumab + MEDI0457 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Withdrawn | USA | 0 |
| NCT03740893 | Phase II | Olaparib Ceralasertib Durvalumab | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX) | Recruiting | GBR | 0 |
| NCT04385368 | Phase III | Durvalumab | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GRC | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 11 |
| NCT03794544 | Phase II | Durvalumab + Oleclumab Danvatirsen + Durvalumab Durvalumab Durvalumab + Monalizumab | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | Completed | USA | ITA | FRA | ESP | CHE | CAN | 1 |
| NCT04269200 | Phase III | Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) | Active, not recruiting | USA | POL | LTU | ISR | HUN | GRC | EST | ESP | DEU | CAN | BRA | BEL | AUS | 9 |
| NCT04262869 | Phase II | Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | Withdrawn | 0 | |
| NCT03916419 | Phase II | Durvalumab Carboplatin + Paclitaxel | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04003246 | Phase III | Durvalumab | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT05925530 | Phase II | Durvalumab | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE) | Recruiting | USA | SWE | ITA | HUN | FRA | ESP | DEU | CZE | CAN | AUT | 1 |
| NCT03703297 | Phase III | Durvalumab Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) | Active, not recruiting | USA | TUR | POL | NLD | ITA | GBR | ESP | DEU | CZE | CAN | BEL | ARG | 7 |
| NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Completed | USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 9 |
| NCT03164616 | Phase III | Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) | Active, not recruiting | USA | POL | HUN | GBR | DEU | BRA | BGR | 12 |
| NCT05000710 | Phase II | Durvalumab Durvalumab + Tremelimumab Tremelimumab | Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung) | Recruiting | ISR | 0 |
| NCT02558894 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | NLD | ESP | DEU | CAN | 1 |
| NCT03693300 | Phase II | Durvalumab | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT03775486 | Phase II | Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) | Active, not recruiting | USA | POL | NLD | HUN | GBR | BEL | 6 |
| NCT04092283 | Phase III | Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Active, not recruiting | USA | 1 |
| NCT06667908 | Phase II | Carboplatin + JNJ-90301900 + Paclitaxel Carboplatin + Paclitaxel Durvalumab | A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (CONVERGE) | Not yet recruiting | USA | 0 |
| NCT03618134 | Phase Ib/II | Durvalumab Durvalumab + Tremelimumab | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | Terminated | USA | 0 |
| NCT03601455 | Phase II | Durvalumab + Tremelimumab Durvalumab | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
| NCT03741426 | Phase II | Durvalumab Cediranib Durvalumab + Olaparib Cediranib + Olaparib Olaparib | WIRE - Novel Treatments in Renal Cell Cancer (WIRE) | Recruiting | GBR | 0 |
| NCT03784066 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO) | Active, not recruiting | BEL | 0 |
| NCT04026412 | Phase III | Nivolumab Ipilimumab + Nivolumab Durvalumab | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | Active, not recruiting | USA | SWE | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 9 |
| NCT02733042 | Phase Ib/II | Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) | Completed | USA | NLD | ITA | GBR | FRA | DEU | 1 |
| NCT03144778 | Phase I | Durvalumab Durvalumab + Tremelimumab | Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO) | Completed | USA | 0 |
| NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
| NCT03446547 | Phase II | Durvalumab | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID) | Recruiting | SWE | NOR | FIN | 0 |
| NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Active, not recruiting | USA | 0 |
| NCT02788773 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | CAN | 0 |
| NCT03624231 | Phase II | Durvalumab Durvalumab + Tremelimumab | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) | Completed | DEU | 0 |
| NCT03410615 | Phase II | Durvalumab + Tremelimumab Cisplatin Durvalumab | Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC | Active, not recruiting | ITA | ESP | CAN | BEL | 0 |
| NCT02678182 | Phase II | Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) | Active, not recruiting | GBR | 0 |
| NCT03288532 | Phase III | Durvalumab Durvalumab + Tremelimumab | Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) | Recruiting | GBR | 0 |
| NCT02336165 | Phase II | Durvalumab Bevacizumab + Durvalumab | Phase 2 Study of MEDI4736 in Patients With Glioblastoma | Completed | USA | AUS | 0 |
| NCT03923270 | Phase I | Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT06331455 | Phase II | Durvalumab | Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER) | Recruiting | CAN | 0 |
| NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Active, not recruiting | USA | 0 |
| NCT04062708 | Phase II | Cisplatin + Docetaxel + Durvalumab Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04585477 | Phase II | Durvalumab | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Recruiting | USA | 0 |
| NCT04073160 | Phase I | Durvalumab Durvalumab + Tremelimumab | TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) | Withdrawn | USA | 0 |
| NCT04108481 | Phase Ib/II | Durvalumab | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) | Suspended | USA | 0 |
| NCT02207530 | Phase II | Durvalumab | Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. | Completed | USA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | 4 |
| NCT02899195 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) | Completed | USA | 0 |
| NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
| NCT06223711 | Phase II | Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | Recruiting | DEU | 0 |
| NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Active, not recruiting | USA | 0 |
| NCT05211895 | Phase III | Durvalumab AB154 + Durvalumab | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) | Recruiting | USA | TUR | ROU | POL | NOR | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | 11 |
| NCT01693562 | Phase Ib/II | Durvalumab | A Phase 1/2 Study to Evaluate MEDI4736 | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | 2 |
| NCT02499328 | Phase Ib/II | Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | 0 |
| NCT04543110 | Phase II | Durvalumab | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT) | Recruiting | CAN | 0 |
| NCT02291055 | Phase Ib/II | Durvalumab ADXS11-001 | Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer | Terminated | USA | 0 |
| NCT06680739 | Phase II | Durvalumab Durvalumab + Tremelimumab | Single cEll pRofiling PErsistaNce To ImmuNothErapy (SERPENTINE) | Recruiting | ESP | 0 |
| NCT02527434 | Phase II | Durvalumab + Tremelimumab Durvalumab | Study of Tremelimumab in Patients With Advanced Solid Tumors | Completed | USA | POL | NLD | BEL | 1 |
| NCT02227667 | Phase II | Durvalumab | Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | Completed | USA | 0 |
| NCT02794883 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | Completed | USA | 0 |
| NCT06124118 | Phase I | Durvalumab Carboplatin + Paclitaxel | Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE) | Recruiting | USA | 0 |
| NCT02891161 | Phase Ib/II | Durvalumab | Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | Unknown status | USA | 0 |
| NCT04245514 | Phase II | Durvalumab | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | Recruiting | DEU | CHE | 0 |
| NCT03801902 | Phase I | Durvalumab + Monalizumab Durvalumab | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial | Suspended | USA | 0 |
| NCT04892953 | Phase II | Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | Recruiting | USA | 0 |
| NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Recruiting | ITA | 0 |
| NCT02340975 | Phase Ib/II | Durvalumab Tremelimumab | A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | Completed | USA | CAN | 4 |
| NCT04642469 | Phase III | Durvalumab | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2) | Completed | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | FRA | ESP | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
| NCT05170204 | Phase III | Durvalumab Alectinib Pralsetinib Entrectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 11 |
| NCT03283943 | Phase I | Durvalumab | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | Unknown status | CAN | 0 |
| NCT04430452 | Phase II | Durvalumab Durvalumab + Tremelimumab | Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition | Recruiting | USA | 0 |
| NCT03802747 | Phase I | Durvalumab + Tremelimumab Durvalumab | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Withdrawn | 0 | |
| NCT03822351 | Phase II | Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) | Completed | USA | POL | ITA | FRA | ESP | CAN | 3 |
| NCT02492867 | Phase 0 | Durvalumab Carboplatin + Paclitaxel | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
| NCT02516241 | Phase III | Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab | Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | 7 |
| NCT02886065 | Phase I | Durvalumab Durvalumab + PVX-410 Durvalumab + Lenalidomide + PVX-410 | A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT04202809 | Phase II | Durvalumab | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) | Recruiting | DEU | 0 |
| NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS | 9 |
| NCT03837899 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab for Pediatric Malignancies | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT02454933 | Phase III | Osimertinib Durvalumab | Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) | Completed | CAN | 2 |
| NCT03277482 | Phase I | Durvalumab + Tremelimumab Durvalumab | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Terminated | USA | 0 |
| NCT02868632 | Phase I | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
CKB BOOST